Nxera focuses on the development of life-changing medicines through investment in science and technology.

Nxera

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Ulrich Aldag

Karsten Henco

Manfred Eigen

Rudolf Rigler

Charles Weissmann

Heinrich M. Schulte

Freimut Leidenberger

Evotec SE

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL  Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Metric
Company Name	Nxera	Evotec SE	Idorsia Ltd	Neurocrine Biosciences, Inc.
Symbol		EVT	IDIA	NBIX
MSH ID	LIFE:NXERA	COM:EVOTEC	COM:IDORSIA	COM:NEUROCRINE
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare		Healthcare
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic		Drug Manufacturers - Specialty & Generic
Country	DE	DE	CH	US
Stage			Post-IPO Debt
Employee Count		5.05K	636	1.45K
Website	nxera.life	evotec.com	idorsia.com	neurocrine.com
LinkedIn
Founders

Metric
Market Cap	1.68B	311.77M	14.81B
Enterprise Value
Monthly Web Traffic	47.49K	19.83K	11.48K
Web Traffic Growth	0.11	1.09	0.19
Valuation
Raised Capital		83.54M

Metric
Revenue	825.37M	173.71M	1.89B
Revenue (LTM)
Revenue (NTM)
Gross Profit	184.89M	143.86M	1.85B
EBITDA	-7.57M	-597.34M	250.90M
Operating Income	-113.11M	-619.04M	250.90M
Net Income	-88.63M	-339.61M	249.70M
EPS	-0.50	-1.90	2.56
Diluted EPS	-0.50	-1.90	2.47
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.27	0.95	0.98
Operating Profit Margin	-0.00	-0.52	0.26
EBITDA Margin	-0.01	-3.44	0.13
Net Profit Margin	-0.11	0.31	0.19
Return on Equity	-0.07	0.44	0.17
Return on Assets	-0.04	0.06	0.11
Return on Capital Employed	-0.00	-0.29	0.19

LIFE:NXERA

Nxera

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.33	-0.73	72.61
P/B Ratio	1.97	-0.33	6.93
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.01	4.46	7.54
EV Multiple	70.97	14.37	35.09

Metric
Days Sales Outstanding	124.70	52.13	85.49
Days Payables Outstanding	61.49	751.10
Days Inventory Outstanding	20.58	2.47K	372.00
Operating Cycle	141.03	2.52K	452.63
Cash Conversion Cycle	93.12	1.77K	452.63
Asset Turnover	0.39	0.28	0.64

Metric
Operating Cash Flow	35.86M	-717.35M	389.90M
Free Cash Flow	-192.28M	-728.06M	361.60M
Cash Flow to Debt	0.05	-0.35	2.52
Operating Cash Flow/Sales	0.04	-3.00	0.33
Free Cash Flow Yield	0.01	-2.60	0.03

Metric
Cash & Equivalents	539.64M	165.35M	251.10M
Accounts Receivable		-14.68M	-89.30M
Inventory	32.63M	67.42M	38.30M
Goodwill	291.13M
Debt to Capitalization	0.36	11.32	0.19
Debt to Assets	0.22	1.85	0.09
Current Ratio	3.18	1.21	2.39
Quick Ratio	1.93	1.00	4.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.18	0.11
R&D to Revenue	0.10	1.94	0.31
SG&A to Revenue	0.04	4.00